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Background: Activation of the immune system is one of the several pathways suggested as involved in Heart
Failure (HF). The complement system is a key component of innate immunity. We hypothesized that comple-
ment proteins C3 and C4 can be an important predictor of death in patients with this condition.
Methods: 380 patients admitted with acute HF were recruited. They were followed up during 6 months. Serum
C3c and C4c proteins were measured and groups were created and compared according to the 25th percentile
cut-off value. A multivariate Cox-regression model was used to establish the prognostic value of both markers
with the endpoints of HF and all-cause death.
Results:Medianpatients' agewas 78 years and 49%of the patientsweremen.Nomajor differenceswere observed
in clinical characteristics of the groups. Patients with lower values of C3c and C4c had signiﬁcantly higher values
of BNP. During the 6 month period of follow up, 63 patients died, and 49 patients were due to HF. C4c showed
univariate prognostic value, but not multivariate value. The multivariate-adjusted Hazard Ratios for the
6 month HF and all-cause death in patients with C3c values below 110.0 mg/dL were, respectively, 2.32 (95%
CI: 1.25–4.28) and 2.52 (95% CI: 1.41–4.49).
Conclusion: Lower C3c levels are independently associatedwith higher risk of death. Our results reinforce the role
of innate immunity in HF pathophysiology.© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The knowledge on the pathophysiology of Heart Failure (HF) has
evolved from a hemodynamic model to a more complex multisystem
syndrome. Several pathways are pointed out as involved in the progres-
sion of this condition. Recently, the activation of the immune systemhas
received considerable interest [1,2]. It is becoming increasingly appar-
ent that inﬂammatory mediators play a crucial role in the development
and perpetuation of HF. In fact, the auto-perpetuation observed in HF
can be, in large part, due to an imbalance between inﬂammatory and
anti-inﬂammatory mediators, in both ischemic and nonischemic HF [3,
4]. These mediators are also known to be related to HF severity and as-
sociatedwith prognosis [2,5]. One of the hallmarks of HFpathogenesis is
the remodeling process. There is now evidence that innate immunity
has a determinant role in this process. In fact, after myocardial injuryliability and freedom from bias
cular do Porto, Faculdade de
ugal. Tel.: +351 912821468.
land Ltd. This is an open access articland damage of cardiac cells, innate immune system must be activated
for a correct regeneration [6–8]. However, long-term chronic innate
immune activation is detrimental as it leads to adverse left ventricular
remodeling and HF worsening. This activation involves a variety of
inﬂammatory molecules and pathways, such as proinﬂammatory cyto-
kines, immune cells, autoantibodies formation and complement activa-
tion [9,10]. The complement system is a key component of the innate
immune system and comprises a cascade of more than 30 proteins.
The complement system has a dual role, as a receptor, for example, for
host infection and as an effector protein that can efﬁciently attract in-
ﬂammatory cells and also directly destroy cells by themembrane attack
complex [11].
We hypothesized that in patients with an episode of acute HF, pro-
teins from the complement system namely C3 and C4 can be involved
in the pathophysiology of HF. We also hypothesized that besides their
involvement, the magnitude of their activation can be related with HF
outcome.
2. Methods
We conducted a prospective observational study between January
2009 and December 2010. During this period, patients admitted to thee under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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with the primary diagnosis of HF, whether worsening or de novo HF,
were eligible for study entry. Patients with acute coronary syndromes,
with complaints attributable to causes other than HF, or with no echo-
cardiographic structural or functional cardiac abnormalities were
excluded.
Treatment decisions, timing of discharge, and discharge medication
were at discretion of the attending physician and the physicians were
aware of the ongoing registry.
An echocardiogram was performed within 72 h of admission to
all eligible patients. Comprehensive echocardiographic assessment
was performed using a multi-frequency matrix probe (Vivid6, GE
Healthcare). The diagnosis of HF was made based on the European
Society of Cardiology guidelines [12]. All HF etiologies were admitted.
Patients with left ventricular systolic dysfunction (LVSD) and with HF
with preserved ejection fraction were included in the registry. Normal
systolic fraction was deﬁned as a left ventricular ejection fraction
(LVEF) above 50%. Treatment and time of discharge were decisions of
the attending physician.
Fasting venous blood samples were collected from all patients be-
tween 7 and 8 am on discharge day. Clinical and demographic data, as
well as other relevant information were collected by interview upon
the collection of the blood sample. B-type natriuretic peptide (BNP)
was measured by a chemiluminescent immunoassay in the Architect
i2000 automated analyzer (Abbott). Creatinine and C-reactive protein
(CRP) were measured in the automated clinical chemistry Olympus
AU5400 analyzer (Beckman-Coulter). C1i, C3c and C4c complement
proteins were measured in the Dimension Vista 1500 nephelometer
(Siemens). Hemoglobin was evaluated in an automated blood counter
Sysmex XE-5000 (Emilio de Azevedo Campos).
Comorbidities were also recorded for each patient. Coronary heart
disease was deﬁned as either history of myocardial infarction, history
or electrocardiographic evidence of ischemia, or coronary angiography
conﬁrmation. Diabetesmellituswas deﬁned as either a history of diabe-
tes or the current prescription of either an oral hypoglycemic agent or
insulin. Anemia was considered when hemoglobin level was below
13 g/dL in men and 12 g/dL in women. Arterial hypertension was de-
ﬁned as the presence of previous diagnosis and record of antihyperten-
sive pharmacological treatment. Renal dysfunction was considered
when creatinine levels exceeded 1.5mg/dL. Estimated glomerular ﬁltra-
tion rate (GFR) was calculated by the Cockcroft–Gault formula [13].
Patientswere followed up during a 6month period after their hospi-
tal discharge, by consulting hospital registries and/or by telephone con-
tact. The endpoints were deﬁned as HF death, including worsening
congestion due to progressive pump failure and sudden cardiac death,
and all-cause mortality.
All patients provided written informed consent to participate in the
study. The study protocol conforms to the ethical guidelines of the dec-
laration of Helsinki and was approved by the local ethics committee.2.1. Statistical analysis
Continuous variables are presented as median (interquartile range)
due to the skewed distribution. Normality of the variables was tested
by the Shapiro–Wilk test. Categorical variables are presented as counts
and proportions.
Patients were divided according to the cut-off value correspondent
to the 25th percentile for C3c and C4c. The groups of patients created
were compared. A Chi-Square test was used for the comparison of cate-
gorical variables. Mann–Whitney test was used for comparing continu-
ous variables once their distribution was skewed.
Kaplan–Meier test was used for estimating the survival function of
patients in the 6 month follow-up with the outcome of HF death.
Spearman's coefﬁcientwas calculated to evaluate the correlation be-
tween continuous variables.A multivariate Cox regression analysis was used to assess the prog-
nostic power of C3c and C4c. Variableswith prognostic impact in an uni-
variate approach or known to inﬂuence HF prognosis in all groups were
also included in the multivariate model built.
The p value considered for statistical signiﬁcance was 0.05 for a con-
ﬁdence interval of 95%.
Data was stored and analyzed using SPSS software (SPSS Inc,
Chicago, Illinois, 20.0).
3. Results
We included 380 patients discharged after hospitalization due to an
acute episode of HF. Patients had a median age of 78 years old
(interquartile (IQ) range: 70–84) andhalf of themweremen (48.7%). Is-
chemic HF etiology was considered in 36.3% of the patients, 56.6% had
systolic HF and 19.3% were discharged with a New York Heart Associa-
tion (NYHA) class of III or IV. Diabetesmellitus and anemiawere comor-
bidities in 45.0% and 42.6% of the patients, respectively. Arterial
hypertension affected 77.1% of the patients, while patients suffering
from renal dysfunction were 22.9%. Almost half of the patients revealed
to have alcohol habits and 36.3% were current or ex-smokers. Patients'
characteristics, comorbidities and laboratory assessments are shown
in Table 1. When divided into groups according to the cut-off value of
the 25th percentile of C3c and C4c, no major differences were noted in
clinical characteristics. However, patients with lower C3c values
showed a signiﬁcantly smaller percentage of history of arterial hyper-
tension. These patients were also less likely to be discharged on statins.
They presented higher values of BNP (median 1188.8 pg/mL vs
602.1 pg/mL) and lower values of C4c and C1i. Patients with lower
C4c values had an identical trend in BNP, C3c and C1i values. At dis-
charge, they were also less likely to be discharged on statins or on
beta-blockers, when compared with the ones with higher values of
C4c (Table 1).
Patients were followed up for 6 months after discharge. During this
period among the 49 patients that died due toHF, 22 had low C3c values
and 21 low C4 values. Estimates revealed a signiﬁcantly higher risk of
death, by HF or other cause, in patients with lower values of C3c and
C4c upon discharge. Fig. 1 shows the survival curves estimator for the
6 month period according to discharge values of the 25th percentile
for C3c (110.0 mg/dL) for HF death endpoint.
Table 2 presents the predictors of 6 month HF and all-cause death in
our group of patients in a univariate approach. These predictors for HF
death were ischemic etiology of HF, NYHA class, history of arterial hy-
pertension, higher BNP and lower hemoglobin, GFR, C3c and C4c values
upon discharge. Besides the strong predictor for HF, BNP, had a hazard
ratio (HR) of 1.02 for HF death (95% CI: 1.01–1.03) and all-cause death
(95% CI: 1.01–1.02) per each 100 mg/dL of increase. Besides BNP, the
markers C3c and C4c were also associated with shorter survival with a
HR of 0.98 (95% CI: 0.97–0.99) and 0.97 (95% CI: 0.95–0.99) for HF
and a HR of 0.98 for both in all-cause death, per eachmg/dL of decrease.
Although C1i showed a signiﬁcant difference between the groups
created, it did not reveal a signiﬁcant HR concerning both endpoints in
study. The prescription of angiotensin converting enzyme inhibitor
and beta-blockers showed to have a signiﬁcant protective effect in
both endpoints.
In themultivariate adjustedmodels, in continuous and quartile anal-
ysis, C3c association with 6 month endpoints was independent of the
other prognostic predictors. The multivariate adjusted HR of 6 month
HF and all-cause death, per mg/dL of C3c values was 0.99 (95% CI:
0.98–1.00). In patients with C3c values lower than 110.0 mg/dL, the
multivariate adjusted HR was 2.32 (95% CI: 1.25–4.28) for HF death
and 2.52 (95 %CI: 1.41–4.49) for all-cause death, comparing with pa-
tients with higher C3c values. For patients with C4c values lower than
25.15mg/dL, themultivariate adjustedHRwas not statistical signiﬁcant,
as well as in the continuous analysis. The multivariate adjusted models
can be observed in Table 3.
Table 1
Patients' demographics, clinical and laboratory characteristics and discharge medication; comparison between C3c and C4c groups.
All patients (n= 380) Low C3c (n= 96) High C3c (n= 284) p
value
Low C4c (n= 95) High C4c (n= 285) p
Value
Clinical characteristics
Age (years), median (IQR) 78 (70–84) 78 (70–84) 77 (70–84) 0.523 76 (69–83) 78 (71–84) 0.582
Male sex, n (%) 185 (48.7) 51 (53.0) 134 (47.0) 0.315 50 (52.6) 135 (47.4) 0.375
Ischemic etiology of HF, n (%) 138 (36.3) 29 (30.2) 109 (38.4) 0.236 31 (32.6) 107 (37.5) 0.512
Preserved LVSF, n (%) 162 (43.4) 45 (27.8) 117 (72.2) 0.370 34 (21.0) 128 (79.0) 0.101
NYHA class at discharge
(III&IV vs I&II), n (%)
73 (19.3) 20 (27.4) 53 (72.6) 0.651 20 (27.4) 53 (72.6) 0.609
Comorbidities
Diabetes mellitus, n (%) 171 (45.0) 36 (37.5) 135 (47.5) 0.088 44 (46.3) 127 (44.6) 0.767
Anemia history, n (%) 162 (42.6) 44 (45.8) 118 (41.5) 0.321 44 (46.3) 118 (41.4) 0.833
Chronic arterial hypertension, n (%) 293 (77.1) 64 (66.7) 229 (80.6) 0.010 70 (73.7) 223 (78.2) 0.293
Chronic renal dysfunction, n (%) 87 (22.9) 22 (22.9) 65 (22.9) 0.147 18 (18.9) 69 (24.2) 0.440
Smoking habits, n (%) current
smoker/ex smoker
29 (7.6)/109 (28.7) 6 (6.3)/27 (28.1) 23 (8.1)/82 (28.9) 0.682 3 (3.2)/28 (29.5) 26 (9.1)/81 (28.4) 0.296
Alcohol habits, n (%) 171 (45.0) 45 (46.9) 126 (44.4) 0.730 43 (45.3) 128 (44.9) 0.931
Laboratory at discharge
Hemoglobin (g/dL), median (IQR) 12.0 (10.8–13.5) 11.7 (10.2–13.0) 12.1 (10.8–13.6) 0.048 11.8 (10.4–13.2) 12.0 (10.8–13.5) 0.170
GFR (mL/min), median (IQR) 39.6 (29.2–52.0) 37.1 (25.8–50.6) 40.4 (29.9–52.7) 0.160 41.8 (31.9–51.3) 38.6 (28.1–52.4) 0.165
BNP (pg/mL), median (IQR) 725.8 (307.5–1369.9) 1188.8 (566.6–1683.2) 602.1 (262.3–1209.2) b0.000 1080.0 (384.4–1735.8) 609.9 (271.1–1284.0) 0.001
CRP (mg/L), median (IQR) 12.2 (6.1–25.0) 12.1 (6.0–21.7) 12.2 (6.1–28.6) 0.388 12.5 (7.3–22.0) 11.9 (6.1–28.7) 0.427
C3c (mg/dL), median (IQR) 130.0 (110.0–149.8) 101.5 (87.1–106.0) 138.0 (126–155) b0.000 110.0 (97.3–132.0) 135.0 (116.5–153.5) 0.000
C4c (mg/dL), median (IQR) 32.3 (25.2–41.1) 24.9 (18.9–29.3) 34.9 (28.8–43.5) b0.000 19.3 (16.0–23.3) 35.9 (30.5–43.7) 0.000
C1i (mg/dL), median (IQR) 32.3 (19.0–36.1) 30.3 (26.8–33.2) 33.4 (30.0–37.2) b0.000 30.7 (26.2–33.6) 33.0 (29.8–37.1) 0.000
Discharge medication
ACEi, n (%) 259 (68.2) 66 (68.8) 193 (68.0) 0.784 65 (68.4) 194 (68.1) 0.984
ARA, n (%) 51 (13.4) 8 (8.3) 43 (15.1) 0.097 11 (11.6) 40 (14.0) 0.537
Spirolactone, n (%) 96 (25.3) 18 (18.8) 78 (27.5) 0.099 24 (25.3) 72 (25.3) 0.986
Beta-blocker, n (%) 303 (79.7) 73 (76.0) 230 (81.0) 0.384 68 (71.6) 235 (82.5) 0.019
Nitrates, n (%) 103 (27.1) 19 (19.8) 84 (29.6) 0.240 21 (22.1) 82 (28.8) 0.429
Statins, n (%) 247 (65.0) 47 (49.0) 200 (70.4) b0.000 50 (52.6) 197 (69.1) 0.002
Diuretic, n (%) 357 (93.9) 89 (92.7) 268 (94.4) 0.713 92 (96.8) 265 (93.0) 0.306
HF death 49 (12.9) 22 (44.9) 27 (55.1) 0.001 21 (42.9) 28 (57.1) 0.002
All cause death 63 (16.6) 29 (46.0) 34 (54.0) b0.000 24 (38.1) 39 (61.9) 0.009
IQR: interquartile range; HF: heart failure; LVSF: left ventricular systolic function; NYHA: New York Heart Association; GFR: estimated glomerular ﬁltration rate; BNP: B-type natriuretic
peptide; CRP: C-reactive protein; C1i: C1 inhibitor; ACEi: angiotensin converting enzyme inhibitor; ARA: angiotensin II receptor antagonist.
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ous variables in study. All complement proteins correlated with each
other, with the stronger correlation between C3c and C4c. BNP had a
negative correlation with C3c and C4c proteins. CRP only positively cor-
related with C3c.Fig. 1. Kaplan–Meier survival curves according to C3c cut-off values of the 25th percentile.
Patients with lower values of C3c had higher 6 month risk of heart failure death after an
acute heart failure episode.4. Discussion
We report that low values of C3c and C4c upon discharge of an acute
HF episode are associatedwith unfavorable outcome in HF patients. The
multivariate adjusted risk of HF or all-cause death at 6 months for pa-
tients with C3c lower than 110.0 mg/dL was about 2.5 fold higher
than for those with higher values at discharge. For C4c, although it
showed prognostic value in a univariate approach, the same did not
come through in a multivariate analysis.
The association between activation of the immune system and HF
has been reported [14,15], with high levels of CRP as an indicative of se-
verity of disease [16]. CRP mediates several protective processes, but
may also have deleterious effects in HF, such as the up-regulation of
tumor necrosis factor α (TNFα) and interleukin (IL)-6 which are a
strong sign of this activation [3,4,17,18]. In fact, circulating levels of
pro-inﬂammatory cytokines are enhanced in the failing myocardium,
in both ischemic and nonischemic HF, and are long known to be related
to disease severity and to predict poor survival [2,5]. Our data also
corroborate this assumption. The levels of CRP, at discharge, had a me-
dian of 12.2 mg/L (IQR: 6.1–25.0) and showed a trend to predict HF
death (p value = 0.063) and a univariate statistical signiﬁcant predic-
tion value for all-cause death (p value = 0.013). Thus, once these are
markers of immune activation and knowing that after an initial heart in-
sult, the increased production of proinﬂammatory cytokines may chal-
lenge the surrounding tissue through propagation of the inﬂammatory
response and direct effects on the cardiac myocyte structure and func-
tion, it is reasonable to assume that the complement proteins may
also contribute to the destructive action of these factors and to the path-
ogenetic sequelae of HF [14].
Table 2
Univariate Cox-regression between patients' characteristics and 6 month heart failure and all-cause death, after an acute heart failure episode.
HF death All-cause death
HR (95% CI) p Value HR (95% CI) p Value
Clinical characteristics, all patients (n= 380)
Age (per year) 1.02 (1.00–1.05) 0.111 1.03 (1.00–1.05) 0.041
Male sex 1.64 (0.92–2.93) 0.092 1.18 (0.72–1.94) 0.503
Ischemic etiology of HF 1.27 (1.05–1.54) 0.016 1.24 (1.03–1.50) 0.023
Preserved LVSF 1.56 (0.86–2.83) 0.146 1.01 (0.61–1.66) 0.983
NYHA class at discharge (III&IV vs I&II) 1.31 (1.08–1.60) 0.007 1.30 (1.09–1.55) 0.004
Comorbidities
Diabetes mellitus 0.87 (0.65–1.16) 0.332 0.83 (0.64–1.07) 0.144
Anemia history 1.00 (0.76–1.32) 0.986 1.12 (0.95–1.32) 0.194
Chronic arterial hypertension 0.47 (0.26–0.85) 0.012 0.50 (0.30–0.86) 0.011
Chronic renal dysfunction 1.11 (0.90–1.37) 0.338 1.23 (1.09–1.40) 0.001
Smoking habits 1.15 (0.95–1.39) 0.166 1.09 (0.90–1.32) 0.364
Alcohol habits 0.92 (0.52–1.63) 0.781 0.80 (0.48–1.33) 0.394
Laboratory at discharge
Hemoglobin (per g/dL) 0.85 (0.73–0.98) 0.030 0.83 (0.73–0.95) 0.007
GFR (per mL/min) 0.98 (0.97–1.00) 0.045 0.98 (0.97–1.00) 0.010
BNP (per 100 pg/mL) 1.02 (1.01–1.03) b0.000 1.02 (1.01–1.02) b0.000
CRP (per 10 mg/L) 1.08 (1.00–1.16) 0.063 1.09 (1.02–1.16) 0.013
C3c (per mg/dL) 0.98 (0.97–0.99) b0.000 0.98 (0.98–0.99) b0.000
C4c (per mg/dL) 0.97 (0.95–0.99) 0.005 0.98 (0.96–0.99) 0.009
C1i (per mg/dL) 0.97 (0.92–1.02) 0.251 0.99 (0.95–1.03) 0.625
Discharge medication
ACEi 0.49 (0.28–0.86) 0.013 0.54 (0.33–0.89) 0.016
ARA 0.56 (0.20–1.56) 0.266 0.66 (0.28–1.53) 0.328
Spirolactone 0.74 (0.37–1.49) 0.397 0.82 (0.45–1.48) 0.509
Beta-blocker 0.39 (0.22–0.69) 0.001 0.49 (0.29–0.83) 0.008
Nitrates 0.82 (0.48–1.42) 0.483 0.86 (0.55–1.35) 0.505
Statins 0.70 (0.40–1.25) 0.226 0.72 (0.43–1.20) 0.207
Diuretic 0.85 (0.41–1.75) 0.657 0.89 (0.51–1.56) 0.691
HR: hazard ratio; IQR: interquartile range; HF: heart failure; LVSF: left ventricular systolic function; LVSD: left ventricular systolic dysfunction; NYHA: New York Heart Association; GFR:
estimated glomerularﬁltration rate; BNP: B-type natriuretic peptide; CRP: C-reactive protein; C1i: C1 inhibitor; ACEi: angiotensin converting enzyme inhibitor; ARA: angiotensin II receptor
antagonist.
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produce complement proteins in ischemic and nonischemic condi-
tions [19,20]. As low complement levels are normally an indicator of
high tissue complement turnover [21,22], the low (peripheral) levels
in patients in our study may represent an increased (local) activation
of complement in the heart. This activation and consequent lower
values can be associated with the poor outcome of our patients, also
supported with the evidence that these patients had signiﬁcant higher
BNP values, representing patients at a higher risk of death due to HF
[23]. In fact, by the Spearman correlation C3c and C4c values signiﬁcant-
ly correlate with BNP values in a negative way. In the heart, activated
complement C3 was already shown to cause tachycardia, impairmentTable 3
Multivariate Cox-regression model for C3c and C4c on 6 month HF death and all-cause
death, after an acute HF episode.
HF deatha All-cause deathb
HR (95% CI) p Value HR (95% CI) p Value
C3c (per mg/dL) 0.99 (0.98–1.00) 0.030 0.99 (0.98–1.00) 0.027
C4c (per mg/dL) 0.98 (0.96–1.01) 0.149 0.98 (0.96–1.00) 0.097
C3c (1st Q vs others) 2.32 (1.25–4.28) 0.008 2.52 (1.41–4.49) 0.002
C4c (1st Q vs others) 1.84 (0.99–3.42) 0.055 1.66 (0.92–3.00) 0.091
HR: hazard ratio; HF: heart failure.
a Model adjusted for: ischemic etiology of heart failure; New York Heart Association
class at discharge (III&IV vs I&II); chronic arterial hypertension; hemoglobin (per g/dL);
estimated glomerular ﬁltration rate; B-type natriuretic peptide (per 100 pg/mL); angioten-
sin converting enzyme inhibitor; beta-blocker medication.
b Model adjusted for: age (per year); ischemic etiology of heart failure; NewYork Heart
Association class at discharge (III&IV vs I&II); chronic arterial hypertension; chronic renal
dysfunction; hemoglobin (per g/dL); estimated glomerular ﬁltration rate; B-type natriuret-
ic peptide (per 100 pg/mL); C-reactive protein (per 10mg/L); angiotensin converting en-
zyme inhibitor; beta-blocker medication.of atrioventricular conduction, left ventricular contractile failure, coro-
nary vasoconstriction, and histamine release after injection into isolated
guinea pig hearts [24]. Thus, besides being a good marker for overall
complement activation, C3 seems to be of pathophysiological relevance
in the cardiovascular system.
The consumption of serum C3 and C4 reﬂects the activation of the
classic and alternate pathways of the complement system [22]. CRP
values besides representing a state of chronic immune activation may
also contribute to the understanding of complement activation. CRP ac-
tivates the classical pathway of complement when bound to appropri-
ate ligands. CRP efﬁciently activates the early proteins of the classical
pathway (C1, C2, C4 and to a lesser extent C3) but does not generate
consumption of the components of the membrane attack complex
(C5–C9) [25]. Surface-boundCRP decreases the alternative complement
pathway C3-convertase and C5-convertase activities, inhibits the alter-
native ampliﬁcation loop and reduces deposition of C3b and lysis by
the lectin pathway [26]. In our patients the values of CRP did correlate
positively with C3c values, but not with C4c. This positive relationship
suggests that CRP can be related with the activation of C3c, by theTable 4
Spearman's correlations.
C1i C3c C4c CRP BNP
C1i Correlation coefﬁcient – 0.369⁎ 0.295⁎ 0.305⁎ −0.070
p value b0.000 b0.000 b0.000 0.174
C3c Correlation coefﬁcient 0.369⁎ – 0.515⁎ 0.106⁎ −0.308⁎
p value b0.000 b0.000 0.040 b0.000
C4c Correlation coefﬁcient 0.295⁎ 0.515⁎ – 0.057 −0.217⁎
p value b0.000 b0.000 0.267 b0.000
C1i: C1 inhibitor; CRP: C-reactive protein; BNP: B-type natriuretic peptide.
⁎ Signiﬁcant correlation.
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C1i in a positive way. The main function of C1i is the inhibition of the
classical pathway of complement to prevent spontaneous activation,
with levels raising about 2 fold during inﬂammation [27,28]. In this
study, the values of C3c and C4c positively correlated with C1i values.
This correlation shows that the activation of the classical pathways
due to a non-inactivation by C1i may also be present in HF.
To our knowledge, this study is the ﬁrst one to strongly establish a
signiﬁcant role for complement as a predictor marker of HF death in
an adjusted survival model. Previous studies have evaluated the pres-
ence and prognostic role of complement system in HF. A study with a
small number of patients (36 participants) with HF registered comple-
ment activation in these patients [29]. In this same study, they have
also shown an association of high SC5b9 levels with 6 month poor out-
come, in an unadjusted model of survival. Another small study with a
similar number of patients with HF (39 participants), also reported a
systemic complement activation attenuatedwith intravenous immuno-
globulin treatment [30]. In a larger study with 118 CHF patients, SC5b9
was also evaluated and correlated with CRP levels. Nevertheless, in
these last two studies, the role as a predictor of deathwas not evaluated.
Clearly, although these studies represent a necessary uncover of the
subject potentiating other studies, the small number of participants
and the absence of adjusted models are major weaknesses. A more re-
cent study in 182 patients reported a signiﬁcant association between
complement C3a higher values and a combined endpoint of all-cause
mortality or rehospitalization due to progression of HF [31]. In this
study, the authors only focused in the analysis of the anaphylotoxin
C3a, although also evaluating C3c and C4c levels. It is true that C3a is a
complement activation product with powerful biological effects; never-
theless this product is rather unstable and degradable upon freezing. In
our study, we measured C3c and C4c, which are more stable comple-
ment products [32]. In another recent study with 197 patients with sta-
ble HF, the authors reported that patients with higher C3c levels
exhibited a trend to better survival but were unable to statistically
prove that prediction [33]. Themajor problem in that report was the di-
vision of the patients according to the assay reference intervals, clearly
not the proper way of studying the value of a biomarker, as was our in-
tention in our cohort. In our study we divided the patients according to
quartiles and in this way we could show an association between those
that belonged to the ﬁrst quartile, with the likelihood of dying due to
complications of HF. Also, and differently from the two studies referred,
as all patients were evaluated at discharge, we may assume with some
level of certainty that they were in the same degree of immune
activation.5. Conclusion
Our results show that upon hospital discharge after an episode of
acute HF, lower values of C3c are associated, BNP independently, with
an approximately 2.5 higher risk of 6 month HF and all-cause death.
Our results suggest that this marker can have a role in the identiﬁcation
of patients at increased risk of mortality.Conﬂict of interests
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